ZA949127B - Prodrugs of an inhibitor of HIV protease - Google Patents
Prodrugs of an inhibitor of HIV proteaseInfo
- Publication number
- ZA949127B ZA949127B ZA949127A ZA949127A ZA949127B ZA 949127 B ZA949127 B ZA 949127B ZA 949127 A ZA949127 A ZA 949127A ZA 949127 A ZA949127 A ZA 949127A ZA 949127 B ZA949127 B ZA 949127B
- Authority
- ZA
- South Africa
- Prior art keywords
- prodrugs
- inhibitor
- hiv protease
- hiv
- protease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15420493A | 1993-11-18 | 1993-11-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA949127B true ZA949127B (en) | 1996-05-17 |
Family
ID=22550424
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA949127A ZA949127B (en) | 1993-11-18 | 1994-11-17 | Prodrugs of an inhibitor of HIV protease |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US5733907A (cs) |
| EP (1) | EP0729467A1 (cs) |
| JP (1) | JPH09505303A (cs) |
| KR (1) | KR960705809A (cs) |
| CN (1) | CN1139432A (cs) |
| AU (1) | AU687128B2 (cs) |
| CA (1) | CA2174649A1 (cs) |
| CZ (1) | CZ140696A3 (cs) |
| FI (1) | FI962073A0 (cs) |
| HU (1) | HUT76270A (cs) |
| IL (1) | IL111584A0 (cs) |
| NO (1) | NO962000D0 (cs) |
| NZ (1) | NZ276622A (cs) |
| PL (1) | PL314486A1 (cs) |
| SK (1) | SK61496A3 (cs) |
| WO (1) | WO1995014016A1 (cs) |
| ZA (1) | ZA949127B (cs) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6458772B1 (en) | 1909-10-07 | 2002-10-01 | Medivir Ab | Prodrugs |
| US20040122000A1 (en) | 1981-01-07 | 2004-06-24 | Vertex Pharmaceuticals Incorporated. | Inhibitors of aspartyl protease |
| US6878728B1 (en) | 1999-06-11 | 2005-04-12 | Vertex Pharmaceutical Incorporated | Inhibitors of aspartyl protease |
| MY126358A (en) * | 1996-03-22 | 2006-09-29 | Glaxo Group Ltd | Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgs |
| US6436989B1 (en) | 1997-12-24 | 2002-08-20 | Vertex Pharmaceuticals, Incorporated | Prodrugs of aspartyl protease inhibitors |
| AU2012199A (en) * | 1997-12-24 | 1999-07-19 | Vertex Pharmaceuticals Incorporated | Prodrugs of aspartyl protease inhibitors |
| FR2773994B1 (fr) * | 1998-01-23 | 2002-10-11 | Univ Nice Sophia Antipolis | Prodrogues issues d'anti-proteases inhibitrices du virus de l'immunodeficience humaine (vih) pour l'amelioration de leur biodisponibilite, de leur tropisme vers et/ou de leur delivrance dans le systeme nerveux central |
| PT1086076E (pt) | 1998-06-19 | 2005-05-31 | Vertex Pharma | Inibidores de sulfonamida de aspartil protease |
| TNSN00027A1 (fr) | 1999-02-12 | 2005-11-10 | Vertex Pharma | Inhibiteurs de l'aspartyle protease |
| MXPA02007252A (es) * | 2000-01-28 | 2003-01-29 | Rohm & Haas | Compuestos farmaceuticos con propiedades mejoradas. |
| US6818787B2 (en) | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US7202092B2 (en) * | 2001-07-13 | 2007-04-10 | Roche Diagnostics Operations, Inc. | Indinavir derivatives useful in immunoassay |
| AU2002316231A1 (en) * | 2002-02-19 | 2003-09-29 | Xenoport, Inc. | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof |
| US8603949B2 (en) * | 2003-06-17 | 2013-12-10 | California Institute Of Technology | Libraries of optimized cytochrome P450 enzymes and the optimized P450 enzymes |
| US7662987B2 (en) * | 2003-07-15 | 2010-02-16 | Xenoport, Inc. | Methods for synthesis of acyloxyalkyl compounds |
| BRPI0413756A (pt) | 2003-08-20 | 2006-10-31 | Xenoport Inc | composto, métodos para tratar ou evitar espasticidade ou um sintoma de espasticidade, doença de refluxo gastro-esofágico, vìcio em droga, vìcio em ou abuso de álcool, ou vìcio em ou abuso de nicotina, e tosse ou êmese em um paciente, e, composição farmacêutica |
| CN102702065A (zh) * | 2003-12-30 | 2012-10-03 | 什诺波特有限公司 | 酰氧基烃基氨基甲酸酯前药及其中间体的合成 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US541168A (en) * | 1895-06-18 | Frank e | ||
| GB1338169A (en) * | 1971-03-09 | 1973-11-21 | Smith Kline French Lab | Ureas thioureas and guanidines |
| US4144346A (en) * | 1977-01-31 | 1979-03-13 | Janssen Pharmaceutica N.V. | Novel 1-(1,3-dioxolan-2-ylmethyl)-1H-imidazoles |
| US4661473A (en) * | 1984-03-27 | 1987-04-28 | Merck & Co., Inc. | Renin inhibitors containing peptide isosteres |
| JPH03500772A (ja) * | 1987-10-21 | 1991-02-21 | ジ・アップジョン・カンパニー | (1‐アミノ‐2‐ヒドロキシ‐2‐ヘテロサイクリック)エチル基を含有するレニン抑制物質類 |
| DK24089D0 (da) * | 1989-01-20 | 1989-01-20 | Hans Bundgaard | Novel prodrug derivatives of biologically active agents containing hydroxyl groups or nh-acidic groups |
| US5218114A (en) * | 1991-04-10 | 1993-06-08 | Merck & Co., Inc. | Cholecystokinin antagonists |
| US5169952A (en) * | 1991-07-02 | 1992-12-08 | Merck & Co., Inc. | Stereoselective production of hydroxyamide compounds from chiral α-amino epoxides |
| ATE163926T1 (de) * | 1991-11-08 | 1998-03-15 | Merck & Co Inc | Hiv-protease-inhibitoren verwendbar in der aids- behandlung |
| US5413999A (en) * | 1991-11-08 | 1995-05-09 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
| US5463067A (en) * | 1993-07-16 | 1995-10-31 | Merck & Co., Inc. | Process for making HIV protease inhibitors |
| DE69426979T2 (de) * | 1993-07-16 | 2001-09-20 | Merck & Co., Inc. | Verfahren zur herstellung von hiv-proteasehemmern |
| WO1995010281A1 (en) * | 1993-10-13 | 1995-04-20 | Merck & Co., Inc. | Combination therapy for hiv infection |
| US5455351A (en) * | 1993-12-13 | 1995-10-03 | Abbott Laboratories | Retroviral protease inhibiting piperazine compounds |
-
1994
- 1994-11-10 IL IL11158494A patent/IL111584A0/xx unknown
- 1994-11-14 WO PCT/US1994/013085 patent/WO1995014016A1/en not_active Ceased
- 1994-11-14 JP JP7514536A patent/JPH09505303A/ja active Pending
- 1994-11-14 FI FI962073A patent/FI962073A0/fi unknown
- 1994-11-14 PL PL94314486A patent/PL314486A1/xx unknown
- 1994-11-14 HU HU9601340A patent/HUT76270A/hu unknown
- 1994-11-14 EP EP95901884A patent/EP0729467A1/en not_active Withdrawn
- 1994-11-14 NZ NZ276622A patent/NZ276622A/en unknown
- 1994-11-14 CZ CZ961406A patent/CZ140696A3/cs unknown
- 1994-11-14 CA CA002174649A patent/CA2174649A1/en not_active Abandoned
- 1994-11-14 SK SK614-96A patent/SK61496A3/sk unknown
- 1994-11-14 KR KR1019960702721A patent/KR960705809A/ko not_active Withdrawn
- 1994-11-14 AU AU10960/95A patent/AU687128B2/en not_active Expired - Fee Related
- 1994-11-14 CN CN94194700A patent/CN1139432A/zh active Pending
- 1994-11-17 ZA ZA949127A patent/ZA949127B/xx unknown
-
1996
- 1996-03-27 US US08/622,945 patent/US5733907A/en not_active Expired - Fee Related
- 1996-05-15 NO NO962000A patent/NO962000D0/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU687128B2 (en) | 1998-02-19 |
| NO962000L (no) | 1996-05-15 |
| NO962000D0 (no) | 1996-05-15 |
| FI962073L (fi) | 1996-05-15 |
| AU1096095A (en) | 1995-06-06 |
| JPH09505303A (ja) | 1997-05-27 |
| SK61496A3 (en) | 1996-11-06 |
| FI962073A7 (fi) | 1996-05-15 |
| NZ276622A (en) | 1997-09-22 |
| FI962073A0 (fi) | 1996-05-15 |
| EP0729467A1 (en) | 1996-09-04 |
| CZ140696A3 (en) | 1996-12-11 |
| WO1995014016A1 (en) | 1995-05-26 |
| PL314486A1 (en) | 1996-09-16 |
| KR960705809A (ko) | 1996-11-08 |
| US5733907A (en) | 1998-03-31 |
| CN1139432A (zh) | 1997-01-01 |
| HU9601340D0 (en) | 1996-07-29 |
| HUT76270A (en) | 1997-07-28 |
| CA2174649A1 (en) | 1995-05-26 |
| IL111584A0 (en) | 1995-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL313871A1 (en) | Inhibitors of hiv protease | |
| PL307858A1 (en) | Sulphonamidic inhibitors of aspartilic hiv protease | |
| PL314838A1 (en) | Inhibitors of bp-iv-serine protease | |
| ZA929869B (en) | Hiv protease inhibitors | |
| PH31249A (en) | Inhibitors of hiv protease. | |
| IL110752A0 (en) | Pharmaceutical composition for an hiv protease inhibitor | |
| ZA943104B (en) | HIV protease inhibitors useful for the treatment of aids | |
| EP0580402A3 (en) | Aminediol protease inhibitors | |
| AU9122391A (en) | Hiv protease inhibitors | |
| ZA949127B (en) | Prodrugs of an inhibitor of HIV protease | |
| EP0691345A3 (en) | Combinations of HIV protease inhibitors | |
| AUPM982594A0 (en) | HIV protease inhibitors | |
| AU6828894A (en) | Hiv protease inhibitors | |
| EP0443560A3 (en) | Hiv protease inhibitors | |
| ZA945234B (en) | Process for making HIV protease inhibitors | |
| EP0594586A4 (en) | Hiv protease inhibitors | |
| ZA984514B (en) | Hiv protease inhibitor | |
| EP0575500A4 (en) | Hiv protease inhibitors | |
| GB9318445D0 (en) | Hiv protease in inhibitor compounds | |
| ZA939480B (en) | Enzyme inhibitor | |
| SG49247A1 (en) | Hiv protease inhibitors | |
| GB9400475D0 (en) | Method of inhibiting HIV protease | |
| SI0774969T1 (en) | Hiv protease inhibitor combination | |
| ZA941501B (en) | Serine protease inhibitors | |
| HU0900220D0 (en) | Hiv protease inhibitors |